TriSalus Life Sciences, Inc. Balance Sheet
TLSI|3 years of annual SEC 10-K data (FY2023-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 3 fiscal years. All figures from audited SEC 10-K filings.
TriSalus Life Sciences, Inc. had $35M in total assets with negative shareholders' equity of $26M as of FY2025. Total debt was $33M against $20M in cash, resulting in $13M net debt.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.11 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash & Equivalents | $20.4M | $11.8M | $11.8M |
| Accounts Receivable | $3.6M | $1.6M | $3.6M |
| Inventory | $3.1M | $2.5M | $2.5M |
| Current Assets | $32.2M | $20.9M | $20.9M |
| PP&E (Net) | $1.8M | $2.1M | $2.1M |
| Total Assets | $35.3M | $24.6M | $25.7M |
| Current Liabilities | $11.5M | $14.7M | $14.7M |
| Total Debt | $33.0M | $0 | - |
| Shareholders' Equity | -$25.9M | -$177.1M | -$176.3M |